Welcome to our dedicated page for Teleflex SEC filings (Ticker: TFX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Teleflex Incorporated (NYSE: TFX) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, including current reports on Form 8-K and other key documents filed with the U.S. Securities and Exchange Commission. These filings offer detailed information on Teleflex’s financial performance, strategic transactions, leadership changes, and capital allocation decisions.
Teleflex uses Form 8-K to report material events such as quarterly and year-to-date financial results, including revenue by region and by global product category (vascular access, interventional, anesthesia, surgical, interventional urology, OEM, and other). The company’s 8-K filings also explain its use of non-GAAP measures like adjusted revenue, adjusted constant currency revenue growth, and adjusted diluted earnings per share, with descriptions of the adjustments for items such as restructuring, impairment, acquisition and divestiture-related costs, separation expenses, regulatory compliance costs, intangible amortization, ERP implementation costs, and tax adjustments.
Filings further document significant corporate actions. For example, Teleflex has filed 8-Ks describing Equity Purchase Agreements to sell its Original Equipment Manufacturing and Development Services business to an affiliate of Montagu and Kohlberg, and to sell its acute care and interventional urology segments to Intersurgical Limited and related entities. These documents outline purchase price terms, closing conditions, regulatory approval requirements, and intended uses of proceeds, including share repurchases and debt reduction.
Governance and leadership developments are also captured in SEC filings. A recent Form 8-K details the departure of the company’s President and Chief Executive Officer, the appointment of Stuart A. Randle as Interim President and Chief Executive Officer, and the designation of Dr. Stephen K. Klasko as Chair of the Board, along with related compensation and severance arrangements.
On Stock Titan, these Teleflex filings are updated as they are released on EDGAR. AI-powered tools can help summarize complex disclosures, highlight key terms in 10-K and 10-Q reports, and surface notable items in Forms 4 and proxy statements, giving investors a clearer view of Teleflex’s financial reporting, insider activity, and governance structure without reading every page manually.
Teleflex Incorporated used this update to respond to Irenic Capital and restate its strategic plan. The company says it remains open to bona fide acquisition proposals but believes its current strategy will create more value. Teleflex highlights previously announced agreements to sell its Acute Care, Interventional Urology and OEM businesses, which are expected to close in the second half of 2026 and generate about $1.8 billion in after-tax net proceeds. It plans to use these proceeds for a $1.0 billion share repurchase and $800 million of debt reduction. Management also points to a multi-year restructuring plan targeting roughly $50 million in annual pre-tax cost savings by mid-2028, with some benefits beginning in 2026, as it focuses the company on higher-growth, higher-margin medical technology segments.
Teleflex Inc. Schedule 13G/A amendment shows The Vanguard Group reporting 0 shares beneficially owned of Teleflex common stock and 0% ownership following an internal realignment. The filing states certain Vanguard subsidiaries will report holdings separately in reliance on January 12, 1998.
The amendment is signed by Ashley Grim, Head of Global Fund Administration, dated 03/27/2026.
Teleflex Incorporated outlines regulatory progress for two planned business divestitures. For its Original Equipment and Manufacturing and Development Services business, the Hart-Scott-Rodino waiting period expired at 11:59 p.m. Eastern Time on March 13, 2026, and completion is anticipated in the third quarter of 2026, subject to remaining regulatory approvals and other conditions.
For its Acute Care and Interventional Urology businesses, Teleflex and Intersurgical Limited received Federal Trade Commission Second Requests on March 11, 2026, extending the HSR waiting period until 30 days after each has substantially complied. This transaction is currently anticipated to close in the second half of 2026, subject to regulatory approvals and specified conditions. The two transactions are separate and may close independently.
Teleflex executive Daniel V. Logue, CVP, General Counsel & Secretary, reported a mix of equity grants and a tax-related share withholding. On March 3, 2026, he received a stock option award for 21,510 shares at $0.00 per share and two common stock awards of 3,262 and 6,591 shares under the Teleflex Incorporated 2023 Stock Incentive Plan. The footnotes state these restricted stock unit and option awards vest in stages between March 3, 2027 and March 3, 2030, subject to his continuous service.
On March 4, 2026, 131 common shares were disposed of at $119.18 per share to satisfy tax liabilities upon vesting of a restricted stock unit award, described as shares withheld rather than an open-market sale. After these transactions, he directly holds 24,652.888 common shares, and an additional 305.683 shares are held indirectly by a 401(k) trustee.
Teleflex Executive Vice President & CFO John Deren reported new equity compensation awards and a small share disposition related to taxes. On March 3, 2026, he acquired 30,362 stock options and two Common Stock restricted stock unit awards totaling 13,784 shares, all granted at no cash cost.
According to the footnotes, one RSU award vests in four 25% installments on 3/3/2027, 3/3/2028, 3/3/2029 and 3/3/2030, and another vests 50% on each of 3/3/2027 and 9/3/2027, in each case subject to his continued service. A stock option grant vests in three equal annual installments on 3/3/2027, 3/3/2028 and 3/3/2029. On March 4, 2026, 229 Common shares were disposed of at $119.18 per share to cover tax withholding upon RSU vesting, leaving him with 18,073 directly held Common shares.
Teleflex Inc. corporate vice president and chief HR officer Cameron P. Hicks reported equity compensation and related tax withholding transactions. On March 3, 2026, he acquired 2,447 shares of common stock and 5,649 shares of common stock as restricted stock unit awards under the Teleflex Incorporated 2023 Stock Incentive Plan, along with a stock option for 16,133 shares. The RSU footnotes state that these awards vest in installments between March 3, 2027 and March 3, 2030, subject to his continued service, and the stock option vests in three annual tranches from March 3, 2027 through March 3, 2029. A separate transaction on March 4, 2026 shows 98 shares of common stock disposed at $119.18 per share to satisfy tax liabilities upon vesting of a restricted stock unit award, leaving 19,362.657 common shares held directly afterward. The filing also notes an indirect holding of 36.916 common shares in a 401(k) plan.
Teleflex Inc. corporate vice president James Winters reported new equity awards and a small share disposition related to taxes. On March 3, 2026, he was granted 21,510 stock options and two restricted stock unit awards of 3,262 and 9,745 common shares, all under the company’s 2023 Stock Incentive Plan.
The RSU awards vest over multiple dates between March 3, 2027 and March 3, 2030, subject to his continued service, while the stock options vest in three equal annual installments starting March 3, 2027. On March 4, 2026, 247 common shares were withheld at $119.18 per share to cover tax obligations upon RSU vesting, leaving him with 17,760 directly owned common shares.
Teleflex Inc. Executive Vice President & CFO John Deren reported a tax-related share disposition. On the vesting of restricted and performance stock units, 231 shares of common stock were withheld at $122.06 per share to satisfy tax liabilities, leaving him with 4,518 directly held shares and 4.377 shares held indirectly through a 401(k) trustee.
Teleflex Inc. corporate vice president and chief HR officer Cameron P. Hicks reported a tax-related share disposition. On February 28, 2026, 396 shares of common stock were withheld to satisfy tax liability upon vesting of restricted and performance stock unit awards at $122.06 per share. After this withholding, Hicks directly held 11,364.657 common shares and indirectly held 36.916 shares through a 401(k) trustee.
Teleflex Inc. executive Daniel V. Logue reported a tax-related share disposition. On the vesting of restricted and performance stock units, 484 shares of common stock were withheld to satisfy tax liabilities at a price of $122.06 per share. After this withholding, he holds 14,930.888 shares directly and 305.683 shares indirectly through a 401(k) trustee.